NCT03990571View on ClinicalTrials.gov

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

March 20, 2023

Study Completion Date

March 20, 2023

Conditions
Metastatic Adenoid Cystic CarcinomaProgressive DiseaseRecurrent Adenoid Cystic Carcinoma
Interventions
DRUG

Avelumab

Given IV

DRUG

Axitinib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03990571 - Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | Biotech Hunter | Biotech Hunter